Aligos Therapeutics patents new inhibitors of PD-1, PD-L1 or PD-1/PD-L1 interaction
Feb. 4, 2025
Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B.